Jesse M. Zaretsky

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being...

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling...

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can be induced in tumors by interferon exposure, leading to immune evasion. This process is important ...

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Abstract Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in pr...